HYPERRHO S/D MINI-DOSE Rx
Generic Name and Formulations:
Rho(D) immune globulin human; 250 IU; per syringe; soln for IM inj.; preservative-free; latex-free.
Grifols Biologicals, Inc.
Indications for HYPERRHO S/D MINI-DOSE:
Prevention of isoimmunization of Rho(D) negative women during spontaneous or induced abortion of ≤12 weeks' gestation when mother is not sensitized to Rho(D) antigen and father is not known to be Rho(D) negative.
Postabortion or miscarriage of up to 12 weeks gestation: 1 syringe IM within 3hrs of spontaneous or induced abortion or within 72hrs following termination of pregnancy.
Contains human plasma; monitor for possible infection transmission. IgA deficiency. Pregnancy (Cat.C).
Avoid live vaccines within 3 months.
Local or infusion reactions.
Report all infections suspected to be transmitted by HyperRHO S/D to (800) 520-2807.
Full dose (Single-dose prefilled syringe)—1; Mini dose (Single-dose prefilled syringe)—10
Endocrinology Advisor Articles
- FDA Approves Admelog Short-Acting Insulin Lispro Injection
- Fertility Hormone Therapy and Cardiovascular Outcomes: What We Know
- Effects of Peer Influence in Adolescents With Type 1 Diabetes
- More Evidence That Saxagliptin Does Not Increase Risk for AMI in Diabetes
- One-Hour Glucose Readings Predict T2D Risk Better Than 2-Hour Measurements
- FDA: Vitamin B7 May Interfere With Lab Tests for Hormone Levels
- Injected and Oral Medications Equally Safe for Gestational Diabetes
- Adjunctive Dapagliflozin Improves Glycemic Control in T1D
- Estradiol Therapy May Benefit Overall Cognition in Postmenopausal Women
- Stopping Postmenopausal HT May Increase Risk for Cardiac, Stroke Death
- Psychosocial Benefits of a Bihormonal Bionic Pancreas System in T1D
- Safety of Chronic Total Occlusion Percutaneous Coronary Intervention in Diabetes
- Oral Insulin Not a Reliable Preventive Strategy for Type 1 Diabetes
- Prevention of Bone Mineral Density Loss Needed in Epilepsy
- Gastric Bypass Blunts B-Cell Sensitivity During Glycemia